|
Lymphocytic Choriomeningitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using a mouse model of acute lymphocytic choriomeningitis virus (LCMV) infection, we observed abundant EZH2 expression and associated H3K27me3 modifications preferentially in the early committed virus-specific T<sub>FH</sub> cells compared to those in T<sub>H</sub>1 cells.
|
30842630 |
2020 |
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-α-synuclein in Parkinson's disease model.
|
31476446 |
2020 |
|
Non-arthropod borne lymphocytic choriomeningitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using a mouse model of acute lymphocytic choriomeningitis virus (LCMV) infection, we observed abundant EZH2 expression and associated H3K27me3 modifications preferentially in the early committed virus-specific T<sub>FH</sub> cells compared to those in T<sub>H</sub>1 cells.
|
30842630 |
2020 |
|
Peritoneal Fibrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We investigated EZH2 expression in peritoneal dialysis (PD) patients and assessed its role in peritoneal fibrosis in cultured human peritoneal mesothelial cells (HPMCs) and murine models of peritoneal fibrosis induced by chlorhexidine gluconate (CG) or high glucose peritoneal dialysis fluid (PDF) by using 3-deazaneplanocin A (3-DZNeP), and EZH2 conditional knockout mice.
|
31579944 |
2020 |
|
PARKINSON DISEASE, LATE-ONSET
|
0.010 |
Biomarker
|
disease |
BEFREE |
An abundance of EZH2 was detected in the peritoneum of patients with PD associated peritonitis and the dialysis effluent of long-term PD patients, which was positively correlated with expression of TGF-β1, vascular endothelial growth factor, and IL-6.
|
31579944 |
2020 |
|
Alcohol Use Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Upregulation of BDNF-AS is associated with a significant decrease in BDNF expression and increased recruitment of EZH2, which deposits repressive H3K27 trimethylation (H3K27me3) at regulatory regions in the BDNF gene in the early onset AUD group.
|
30728347 |
2019 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we find that PRC2 target genes are derepressed and the RNA binding subunit EZH2 largely insoluble in postmortem brain samples from ALS/FTD patients with <i>C9ORF72</i> (C9) repeat expansions, leading to the hypothesis that the (G<sub>4</sub>C<sub>2</sub>)<sub>n</sub> repeat RNA might be sequestering PRC2.
|
31048495 |
2019 |
|
Anxiety
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together our results suggest that loss of miR-137 contributes to the etiology of anxiety, and EZH2 might be a potential therapeutic target for anxiety and depressive phenotypes associated with the dysfunction of miR-137.
|
31736707 |
2019 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Together our results suggest that loss of miR-137 contributes to the etiology of anxiety, and EZH2 might be a potential therapeutic target for anxiety and depressive phenotypes associated with the dysfunction of miR-137.
|
31736707 |
2019 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that targeting EZH2 or EZH2-regulated genes might present therapeutic potential in AF.
|
31408621 |
2019 |
|
Chondrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, this effect was not correlated to EZH2 expression nor activity, and EZH2 knock-down by siRNA did not reduce CS viability.
|
31613064 |
2019 |
|
Coronary Arteriosclerosis
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, we identify EZH2 as an epigenetic regulator of KLF15 along with DNA hypermethylation, and we propose a novel mechanism through which coronary heart disease reprograms the expression of both intermediate enzymes and upstream regulators of cardiac metabolism such as KLF15.
|
30089854 |
2019 |
|
Coronary heart disease
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, we identify EZH2 as an epigenetic regulator of KLF15 along with DNA hypermethylation, and we propose a novel mechanism through which coronary heart disease reprograms the expression of both intermediate enzymes and upstream regulators of cardiac metabolism such as KLF15.
|
30089854 |
2019 |
|
Endometrial cystic hyperplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In summary, uterine EZH2 expression is developmentally and hormonally regulated, and its loss causes aberrant uterine epithelial proliferation, uterine hypertrophy, and cystic endometrial hyperplasia, indicating a critical role in uterine development and function.
|
31201420 |
2019 |
|
Scleroderma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting EZH2 or EZH2-regulated genes might be of therapeutic potential in SSc.
|
30755532 |
2019 |
|
Ependymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recently, we reported CXorf67 overexpression as hallmark of PFA ependymoma and showed that CXorf67 can interact with EZH2 thereby inhibiting polycomb repressive complex 2 (PRC2), but the mechanism of action remained unclear.
|
30923826 |
2019 |
|
Angioimmunoblastic Lymphadenopathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Additionally, 67.5% of patients with PTCL-NOS, 50% of patients with NK/TCL, 73.3% of patients with ALCL and 60% of patients with AITL highly expressed EZH2.
|
31423206 |
2019 |
|
Immunologic Deficiency Syndromes
|
0.010 |
GeneticVariation
|
group |
BEFREE |
HSC from PMF patients with double ASXL1/EZH2 mutations exhibited significantly higher engraftment in immunodeficient mice than those from patients without histone modifier mutations.
|
29907810 |
2019 |
|
Leukemia, Mast-Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we elucidated the role of EZH1 and EZH2 overexpression by immunohistochemistry and correlated them to clinical outcome in 41 MCL patients.
|
31565482 |
2019 |
|
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We sought to determine whether the polycomb repressive complex 2 protein enhancer of zeste homolog 2 (Ezh2) restrains pathogenicity of NKT cells in the context of asthma-like lung disease.
|
30851295 |
2019 |
|
Neural Tube Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
This study established the role of transcription factor Sox19b and epigenetic factor EZH2 regulatory network on NSC development, which provides new clues and theoretical guidance for the clinical treatment of neural tube defects.
|
31842983 |
2019 |
|
Osteoporosis, Postmenopausal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Silencing of LncRNA-ANCR Promotes the Osteogenesis of Osteoblast Cells in Postmenopausal Osteoporosis via Targeting EZH2 and RUNX2.
|
31347330 |
2019 |
|
Peripheral T-Cell Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
EZH2 expression was significantly correlated with the presence of B symptoms, elevated LDH and elevated β2 microglobulin (B2M; P<0.05), and HDAC2 expression was significantly correlated with sex, advanced clinical stages, high international prognostic index scores and elevated B2M levels (P<0.05) in all the patients with PTCL.
|
31423206 |
2019 |
|
Intervertebral Disc Degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
This work explored the role of histone methyltransferase enhancer of zeste homologue 2 (EZH2) in CEP degeneration, as well as its underlying epigenetic mechanisms, and confirmed the effect of EZH2 knockdown on delaying IVDD development.
|
31631036 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DAB2IP Expression in Abdominal Aortic Aneurysm: EZH2 and mir-363-3p as Potential Mediators.
|
31028191 |
2019 |